Biolegend, 307405, PE anti-human CD262 (DR5, TRAIL-R2) Antibody, 25tests

DR5 is 55 kD member 10B of the TNF receptor superfamily (TNFRSF10B), also known as TRAIL-R2, TRICK2, KILLER, and CD262. It binds the cytotoxic ligand TRAIL and induces apoptosis. The DR5 receptor is broadly expressed on a variety of normal tissues and many tumors. DR5 expression has been reported to be upregulated in human cells by interferon-α, 2-methoxyestradiol, and paclitaxel, and downregulated by adenoviral E3 proteins.
25tests
Verified Reactivity: Human
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: Extracellular domain of DR5-human IgG1 Fc fusion protein
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.
Excitation Laser: Blue Laser (488 nm)Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application References(PubMed link indicates BioLegend citation): Uno K, et al. 2003. Blood 101:3658. Sato K, et al. 2005. J. Immunol. 174:4025. Lundgvist A,et al.2006.Cancer Res.14:7317.PubMed
Product Citations: Braun F, et al. 2015. PLoS One. 10:117994. PubMed Cox MJ, et al. 2022. Leukemia. 36:1635. PubMed Lin CP, et al. 2023. EMBO J. 42:e111614. PubMed Grayson KA, et al. 2021. Mol Cancer Ther. 20:833. PubMed Jeong D, et al. 2021. eLife. 0.416666666666667. PubMed Ng W, et al. 2021. Pharm Biol. 59:47:00. PubMed Vunnam N, et al. 2017. Biophys J. 10.1016/j.bpj.2017.05.038. PubMed Wu Y, et al. 2019. Sci Rep. 9:20301. PubMed Yerbes R, et al. 2022. Cell Death Dis. 13:906. PubMed Bernareggi D, et al. 2022. Nat Commun. 13:1899. PubMed Magnussen G, et al. 2012. Biochem Biophys Res Commun. 420:516. PubMed Grayson KA, et al. 2021. PLoS One. 16:e0246733. PubMed Greenlee JD, et al. 2021. eLife. 0.416666666666667. PubMed Volpin V, et al. 2020. Cancer Immunol Res. 8:1163. PubMed Yao C, et al. 2018. Autophagy. 1.854861111. PubMed Ray JE, et al. 2021. Cancer Biol Ther. 22:554. PubMed Kolluri KK et al. 2018. eLife. 7 pii: e30224. PubMed Brin E, et al. 2018. Oncotarget. 9:36914. PubMed Stolfi C, et al. 2011. Mol Cancer Ther. 1.159027778. PubMed Choi Y, et al. 2015. Gut. 64: 1303-1313. PubMed Ishii Y, et al. 2021. J Biol Chem. 297:101223. PubMed Canestraro M, et al. 2010. Cancer Genet Cytogenet. 199:110. PubMed
RRID: AB_314677 (BioLegend Cat. No. 307405) AB_2204926 (BioLegend Cat. No. 307406)
Structure: TNFR superfamily, 55 kD
Distribution: Broadly expressed on normal and tumor cells
Function: Induces apoptosis
Ligand/Receptor: TRAIL
Biology Area: Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Immunology
Molecular Family: CD Molecules, Cytokine/Chemokine Receptors
Antigen References: 1. MacFarlane M, et al. 1997. J. Biol. Chem. 272:25417. 2. Walczak H, et al. 1997. EMBO J. 16:5386. 3. Shigeno M, et al. 2003. Oncogene 22:1653. 4. LaVallee T, et al. 2003. Cancer Res. 63:468. 5. Nimmanapalli R, et al. 2001. Cancer Res. 61:759
Gene ID: 8795
UniProt: View information about CD262 on UniProt.org
Clone: DJR2-4 (7-8)
Regulatory Status: RUO
Workshop: HCDM listed
Other Names: TRAIL-R2, KILLER, TRICK2, TNFRSF10B, Ly98, CD262
Isotype: Mouse IgG1, κ
Q: What type of PE do you use in your conjugates?
A: We use R-PE in our conjugates.